window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

biomarkers

  • Digital & Data,Drug Discovery & Development,Research & Development

    NVision deploys quantum-enhanced MRI platform at Hokkaido University

    NVision has deployed its POLARIS quantum-enhanced MRI platform at Hokkaido [...]

    September 14, 2026
  • Drug Discovery & Development,Genomics and sequencing,Research & Development

    Tagomics launches cfDNA platform for multi-organ drug safety monitoring

    Tagomics has launched a cell-free DNA platform designed to monitor [...]

    August 17, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    BioVie reports Phase 2 Parkinson’s trial results for bezisterim

    BioVie has reported topline results from a Phase 2 trial [...]

    August 7, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    ABLi reports biomarker changes supporting disease-modifying potential of Parkinson’s drug

    ABLi Therapeutics has reported coordinated changes across 11 biomarkers linked [...]

    August 4, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    ProMIS reports no ARIA-E in Phase 1b Alzheimer’s trial of PMN310

    ProMIS Neurosciences has reported six-month interim safety and biomarker data [...]

    July 29, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    ProMIS reports first human evidence of PMN310 target engagement in Alzheimer’s disease

    ProMIS Neurosciences has reported the first human evidence that its [...]

    July 14, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Inocras and AimedBio partner on whole genome sequencing for ADC trials

    Inocras and AimedBio have formed a strategic partnership to integrate [...]

    July 2, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Nine-gene signature linked to lapatinib resistance in HER2-positive breast cancer

    Researchers at City St George’s, University of London have identified [...]

    May 5, 2026
  • Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    Genomics and sequencing: Sapient study uses rLC-MS to map metabolic aging and disease insights in 26,000 samples

    Sapient has published a large-scale metabolomics study using its rapid [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Nautilus and the Allen Institute partner to map tau proteoforms in Alzheimer’s disease research

    Nautilus Biotechnology has announced a new collaboration with the Allen [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Sapience Therapeutics gets FDA clearance for ST316 FAP study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • EURneffy recommended for emergency anaphylaxis treatment in NHS Wales
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Lifebit awarded three-year NIHR BioResource research environment contract
    Categories: Biotech & Pharma Business, Digital & Data, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top